{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:51:58Z","timestamp":1791327118081,"version":"4.3.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007311","name":"Cleveland Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007311","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.leukres.2026.108325","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:08:54Z","timestamp":1790035734000},"page":"108325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comorbidity burden is a major independent prognostic factor in Waldenstr\u00f6m Macroglobulinemia: A national cancer database retrospective study"],"prefix":"10.1016","volume":"171","author":[{"given":"Gaelle C.","family":"Haddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7334-189X","authenticated-orcid":false,"given":"Aaron","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Galili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3664-3449","authenticated-orcid":false,"given":"Chieh-Lin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chakra P.","family":"Chaulagain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108325_bib1","unstructured":"Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al. WHO classification of tumours of haematopoietic and lymphoid tissues: International agency for research on cancer Lyon, France; 2008."},{"issue":"1","key":"10.1016\/j.leukres.2026.108325_bib2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/ajh.23351","article-title":"Patterns of survival in lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005","volume":"88","author":"Kristinsson","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108325_bib3","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia","volume":"367","author":"SP","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2026.108325_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.14196","article-title":"Recommendations for the diagnosis and initial evaluation of patients with Waldenstr\u00f6m Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenstr\u00f6m Macroglobulinaemia","volume":"175","author":"Castillo","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"9873","key":"10.1016\/j.leukres.2026.108325_bib5","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.leukres.2026.108325_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"iNNOVATE Study Group and the European Consortium for Waldenstr\u00f6m's Macroglobulinemia. Ibrutinib for patients with rituximab-refractory Waldenstr\u00f6m's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol."},{"issue":"18","key":"10.1016\/j.leukres.2026.108325_bib7","first-page":"2038","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"11","key":"10.1016\/j.leukres.2026.108325_bib8","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1038\/s41375-019-0431-y","article-title":"A revised international prognostic score system for Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"33","author":"Kastritis","year":"2019","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.leukres.2026.108325_bib9","first-page":"4163","article-title":"International prognostic scoring system for Waldenstr\u00f6m macroglobulinemia","volume":"113","author":"Morel","year":"2009","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108325_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/bjh.13264","article-title":"Overall survival and competing risks of death in patients with Waldenstr\u00f6m macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database","volume":"169","author":"Castillo","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108325_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"issue":"3","key":"10.1016\/j.leukres.2026.108325_bib12","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","article-title":"The National Cancer Data Base: a powerful initiative to improve cancer care in the United States","volume":"15","author":"Bilimoria","year":"2008","journal-title":"Ann. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108325_bib13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/bjh.18680","article-title":"The Rory Morrison WMUK Registry for Waldenstr\u00f6m macroglobulinaemia: The growth of a national registry for a rare disorder","volume":"201","author":"Uppal","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2026.108325_bib14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/ajh.27666","article-title":"Waldenstr\u00f6m Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management","volume":"100","author":"Gertz","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108325_bib15","article-title":"Validation of novel prognostic models in symptomatic Waldenstr\u00f6m's macroglobulinemia based on real-world data","author":"Kascak","year":"2025","journal-title":"Am. Soc. Hematol. Wash. DC"},{"key":"10.1016\/j.leukres.2026.108325_bib16","article-title":"Causes of death among Waldenstr\u00f6m macroglobulinemia patients: A population-based study","author":"Li","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"6","key":"10.1016\/j.leukres.2026.108325_bib17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/bjh.16492","article-title":"Cause-specific mortality in individuals with lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinaemia, 2000-2016","volume":"189","author":"Dalal","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2026.108325_bib18","article-title":"Impact of Comorbidities on Patients With Waldenstr\u00f6m Macroglobulinemia in Taiwan: A Multicenter Study","volume":"11","author":"Chang","year":"2025","journal-title":"JCO Glob. Oncol."},{"issue":"13","key":"10.1016\/j.leukres.2026.108325_bib19","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/cncr.29334","article-title":"Incidence of secondary malignancies among patients with W aldenstr\u00f6m macroglobulinemia: An analysis of the SEER database","volume":"121","author":"Castillo","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2026.108325_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e19046","article-title":"Impact of demographic and socioeconomic factors on survival outcomes in patients with Waldenstrom macroglobulinemia: A SEER database analysis from 2000-2021","author":"Peshin","year":"2025","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2026.108325_bib21","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1182\/bloodadvances.2024013956","article-title":"Socioeconomic, racial-ethnic, household, and infrastructural disparities of hematologic cancer outcomes in the United States","volume":"9","author":"Fei-Zhang","year":"2025","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.leukres.2026.108325_bib22","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1080\/10428194.2022.2102623","article-title":"Insurance-based disparities impact survival outcomes in Waldenstr\u00f6m macroglobulinemia within the United States","volume":"63","author":"Chohan","year":"2022","journal-title":"Leuk. & Lymphoma"},{"issue":"8","key":"10.1016\/j.leukres.2026.108325_bib23","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/ajh.24052","article-title":"Survival outcomes of secondary cancers in patients with Waldenstr\u00f6m macroglobulinemia: an analysis of the SEER database","volume":"90","author":"Castillo","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108325_bib24","series-title":"Seminars in hematology","article-title":"editors. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-na\u00efve patients","author":"Buske","year":"2023"},{"issue":"6","key":"10.1016\/j.leukres.2026.108325_bib25","first-page":"721","article-title":"How I treat Waldenstr\u00f6m macroglobulinemia","volume":"126","author":"Treon","year":"2015","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108325_bib26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.2008.17.7865","article-title":"Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia","volume":"27","author":"Dimopoulos","year":"2009","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:26:14Z","timestamp":1791325574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626001694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":26,"alternative-id":["S0145212626001694"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108325","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comorbidity burden is a major independent prognostic factor in Waldenstr\u00f6m Macroglobulinemia: A national cancer database retrospective study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108325","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108325"}}